All Organoids articles
-
NewsHow researchers are recreating the human heart in the lab
Many promising therapies fail because preclinical models do not fully capture the complexity of the human heart. A new review explores how 3D cardiac constructs could improve disease modelling, drug screening and safety assessment.
-
NewsCardiac organoids repair heart attack damage in preclinical study
Researchers have developed a scalable bioreactor-based system to produce cardiac organoids that successfully integrated into damaged heart tissue in porcine models of myocardial infarction, improving cardiac function and reducing scar formation without triggering arrhythmias.
-
NewsOrganoid study reveals valproate’s impact on developing brain
German researchers have used cerebral organoids to investigate how the epilepsy medication valproate interferes with early brain development, identifying significant disruption to the extracellular matrix and neuronal maturation that may explain increased neurodevelopmental risks in exposed foetuses.
-
News3D-printed system doubles growth speed of transplantable gut organoids
A novel 3D-printed confined culture system has enabled researchers to generate larger, more advanced human gastrointestinal organoids in half the time of traditional methods, producing transplantation-ready tissues with self-organised enteric neural networks within 14 days.
-
NewsISSCR consortium submits recommendations on NAMs to FDA
The ISSCR Consortium on Advanced Stem Cell-Based Models is calling for greater flexibilty from the FDA to accomodate rapidly changing technologies like stem cell-derived systems, organoids and computational approaches.
-
ArticleTurning CRISPR hits into confident drug discovery decisions
Functional genomics is central to modern drug discovery, yet high attrition rates persist. In this article, Dr Salman Tamaddon-Jahromi, a postdoctoral research associate at the University of Cambridge, discusses how end-to-end CRISPR screening strategies, iPSC-derived neuronal models and layered quality control can convert functional genomics signals into actionable therapeutic hypotheses.
-
ReportOrganoids and Organ Chips: Improving Decision-Making in Early Drug Discovery
Early drug discovery has no shortage of models, but predicting what will translate to patients remains difficult. This report examines how organoids, organ-on-chip systems and imaging technologies are used to measure drug response, analyse resistance mechanisms and assess how well findings reflect clinical outcomes in human-relevant models.
-
ArticleWhy lower organisms matter for neurodegeneration drug discovery
In the wake of recent government policy aimed at actively replacing animal models in drug discovery, we consider a possible solution to the translational shortfalls of current cellular methodologies for neurodegenerative disease.
-
NewsChampions Oncology to present eight studies at AACR 2026
Champions Oncology will present eight studies at AACR 2026 spanning KRAS-mutant tumours, ovarian cancer, glioblastoma and emerging therapies including radiopharmaceuticals and CAR-T, using patient-derived models to improve early-stage decision-making in oncology drug development.
-
NewsScientists link IVNS1ABP gene to new ageing disorder
An international research team has identified a previously unknown genetic disease characterised by premature ageing and progressive neurological decline. Using genome sequencing combined with induced pluripotent stem cell technology, scientists traced the condition to a mutation in the IVNS1ABP gene and uncovered disrupted actin dynamics during cell division as the underlying pathological mechanism.
-
WebinarWhat it takes to automate high-content imaging at scale
This webinar examines the design trade-offs and technical constraints involved in building a high-throughput robotic imaging pipeline for complex biological workflows.
-
NewsPRI-101 could become first disease-modifying Parkinson’s drug
Biotechnology company Priavoid GmbH has announced proof-of-concept data for PRI-101, an orally available peptide drug targeting neurodegeneration. Preclinical studies demonstrate the experimental therapy reduces toxic α-synuclein aggregates across multiple Parkinson’s disease models, with evidence of blood-brain barrier penetration and improved survival outcomes.
-
ArticleDiscovery is changing – and automation leads the way
Automation is helping drug discovery teams screen faster, cut costs and run complex assays at scale – but its real value lies in what happens next.
-
ArticlePreclinical takeaways from the World ADC Conference London
Experts from the World ADC Conference in London highlight how patient-centric, predictive preclinical tools and innovative ADC designs are improving safety, efficacy and clinical translation.
-
ArticleReplacing animals in science: what the UK’s new strategy means
The UK has set out a strategy to replace animal testing, but delivering change will depend as much on regulation as on technology. Dr Emma Grange, Director of Science and Regulatory Affairs at Cruelty Free International, examines what the policy signals for research, drug discovery and safety assessment.
-
NewsNew organoid model helps test spinal cord regeneration drugs
Northwestern scientists have grown human spinal cord organoids to test therapies that could reduce scarring and promote nerve regrowth in patients.
-
NewsNew OC-PAM AI tool tracks cancer organoid drug response
Scientists have developed an AI-enhanced imaging platform that enables non-invasive, label-free and longitudinal monitoring of cancer organoids and spheroids.
-
NewsNew paper warns against phasing out animal testing too quickly
A push by the US Food and Drug Administration to phase out animal testing in drug development could improve efficiency and reduce animal suffering, but experts warn that moving too quickly may pose risks to patient safety.
-
NewsMini-stomach organoids grown to improve disease research
Scientists have grown the first multi-regional “mini-stomach” in the lab, creating a new way to study rare genetic stomach diseases and help to develop new treatments for digestive conditions.
-
ArticleDrug development in 2026: NAMs, safety and regulatory changes
2026 is set to be a pivotal year for drug discovery, with advances in NAMs and evolving regulatory approaches promising faster, safer early drug development and accelerated delivery of therapies for patients with rare or unmet medical needs.